Valuation: CSL Limited

Market Cap 4.14TCr 3.6TCr 3.35TCr 3.07TCr 5.8TCr 3,94900Cr 5.89TCr 39TCr 15TCr 1,96600Cr 16TCr 15TCr 6,59300Cr P/E 2026 *
-46.3x
P/E 2027 * 28.8x
Enterprise Value 5TCr 4.35TCr 4.04TCr 3.71TCr 7.01TCr 4,77100Cr 7.12TCr 48TCr 19TCr 2,37500Cr 19TCr 18TCr 7,96500Cr EV / Sales 2026 *
3.25x
EV / Sales 2027 * 3.16x
Free-Float
99.3%
Yield 2026 *
3.29%
Yield 2027 * 3.38%
1 day-4.90%
1 week+7.98%
Current month+7.66%
1 month+5.35%
3 months-3.59%
6 months-30.41%
Current year-25.01%
1 week 20.17
Extreme 20.17
22.76
1 month 19.91
Extreme 19.91
22.76
Current year 16.01
Extreme 16.01
33.53
1 year 16.01
Extreme 16.01
44.77
3 years 16.01
Extreme 16.01
54.5
5 years 16.01
Extreme 16.01
58.62
10 years 16.01
Extreme 16.01
58.99
Manager TitleAgeSince
Chief Executive Officer 63 11/02/2026
Director of Finance/CFO 52 07/10/2025
Chief Operating Officer - 01/05/2025
Director TitleAgeSince
Director/Board Member 72 17/10/2018
Director/Board Member 70 02/02/2011
Director/Board Member 71 09/12/2019
Change 5-day change 1-year change 3-year change Capi.($)
-3.26%+7.98% - - 4.29TCr
+2.07%+15.32%+38.70%+1.97% 7.51TCr
+2.72%-9.39%+17.04%+176.83% 4.76TCr
-2.75%+48.50%+48.50%+48.50% 4.95TCr
-1.33%+1.77%+60.75%-23.85% 3.07TCr
-2.37%+2.14%+60.49%+88.62% 2.49TCr
-3.84%+3.47%+89.26%-52.45% 2.3TCr
-1.59%-4.78%-11.93%+136.89% 1.96TCr
-0.42%+2.89%+74.55%+128.45% 1.72TCr
-2.67%-4.62%+69.54%+128.91% 1.61TCr
Average -1.49%+1.77%+49.65%+70.43% 3.37TCr
Weighted average by Cap. -0.92%+2.46%+45.14%+59.92%

Financials

2026 *2027 *
Net sales 1.54TCr 1.34TCr 1.24TCr 1.14TCr 2.16TCr 1,46800Cr 2.19TCr 15TCr 5.76TCr 73TCr 5.78TCr 5.65TCr 2,45100Cr 1.56TCr 1.35TCr 1.26TCr 1.16TCr 2.19TCr 1,48800Cr 2.22TCr 15TCr 5.83TCr 74TCr 5.85TCr 5.72TCr 2,48300Cr
Net income -97Cr -84Cr -78Cr -72Cr -135.62Cr -9.23TCr -137.72Cr -922Cr -361.86Cr -4.59TCr -363.05Cr -355.08Cr -15TCr 118.46Cr 102.97Cr 96Cr 88Cr 166.18Cr 11TCr 168.75Cr 1.13TCr 443.41Cr 5.63TCr 444.88Cr 435.1Cr 19TCr
Net Debt 861.4Cr 748.82Cr 696.99Cr 639.92Cr 1.21TCr 82TCr 1.23TCr 8.22TCr 3.22TCr 41TCr 3.24TCr 3.16TCr 1,37300Cr 786.6Cr 683.79Cr 636.46Cr 584.35Cr 1.1TCr 75TCr 1.12TCr 7.5TCr 2.94TCr 37TCr 2.95TCr 2.89TCr 1,25300Cr
Logo CSL Limited
CSL Limited is an Australia-based biotechnology company. The Company’s areas of focus include rare and serious diseases, influenza vaccines and iron deficiency and nephrology. The Company’s segments include CSL Behring, CSL Seqirus and CSL Vifor. The CSL Behring segment manufactures, markets and distributes plasma products, gene therapies and recombinants. The CSL Seqirus segment manufactures, markets and distributes predominantly influenza related products and provides pandemic services to governments. The CSL Vifor segment manufactures, markets and distributes products in the therapeutic areas of iron deficiency and nephrology. Its CSL Plasma operates plasma collection networks, with approximately 325 plasma collection centers in the United States, Europe and China. The Company operates in Australia, the United States, Germany, the United Kingdom, Switzerland and China (including Hong Kong). Its products include Respreeza, Zemaira, HAEGARDA, KCENTRA, Hepatitis B, Evogam, and others.
Employees
29,904
Date Price Change Volume
31/26/31 $21.97 -3.26% 1,38,526
30/26/30 $22.71 +2.34% 2,14,430
29/26/29 $22.19 +5.27% 3,15,637
28/26/28 $21.08 +3.64% 2,60,716
27/26/27 $20.34 +1.70% 3,16,371
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
16
Last Close Price
86.26USD
Average target price
97.43USD
Spread / Average Target
+12.95%

Quarterly revenue - Rate of surprise